Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Colorectal Cancer Reports
Published in: Current Colorectal Cancer Reports 2/2013

01-06-2013 | Colorectal Cancer Hepatic Metastases (KK Tanabe, Section Editor)

Use of Chemotherapy in the Resection of Liver Metastases of Colorectal Cancer

Authors: Anya Litvak, Leonard Saltz

Published in: Current Colorectal Cancer Reports | Issue 2/2013

Login to get access

Abstract

R0 resection has proved curative in a subset of patients with colorectal liver metastases. Unfortunately, the incidence of recurrence is high. For this reason, chemotherapy has been used at the preoperative and/or postoperative settings in clearly resectable disease in an attempt to eradicate micrometastasis and, hopefully, increase the oncological benefit of resection. For patients whose disease is not resectable but would become resectable as a result of a substantial response to treatment, chemotherapy is used to “convert” unresectable to resectable disease. This paper will review the use of perioperative chemotherapy, discuss issues regarding administration of chemotherapy before or after surgery, and review evidence regarding the use of specific cytotoxic and targeted agents.
Literature
1.
2.
3.
• Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomized controlled trial. Lancet. 2008;371:1007–16. This is the first trial to demonstrate the oncological benefit of perioperative chemotherapy in liver resection.PubMedCrossRef
4.
Mitry E, Fields A, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials. JCO. 2008;26:4906–11.CrossRef
5.
Nordlinger B, Sorbye H, Glimelius B, et al. EORTC liver metastases intergroup randomized phase III study 40983: long-term survival results. JCO. 2012 (suppl; abstr 3508).
6.
Saltz, Leonard. Curative Intent Treatment for Colorectal Liver Metastases: The medical Oncologist’s perspective. 2012 Educational Book.
7.
Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004;240(6):1052–61.PubMedCrossRef
8.
Brazer DG, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. JCO. 2008;26(33):5344–51.CrossRef
9.
Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90 day mortality after surgery for hepatic colorectal metastases. JCO. 2006;24(13):2065–72.CrossRef
10.
Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15(3):460–6.PubMedCrossRef
11.
Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247(1):118–24.PubMedCrossRef
12.
Masi G, Loupakis F, Pollina L, et al. Long term outcome of initially unresectable metastatic colorectal cancer patients treated with FOLFOXIRI followed by radical surgery of metastases. Ann Surg. 2009;249:420–5.PubMedCrossRef
13.
Kesmodel SB, Ellis LM, Lin E, et al. Preoperative bevacizumab does not significantly increase postoperative complications rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. JCO. 2008;26:5254–60.CrossRef
14.
Tan MC, Linehan DC, Hawkins WG, Siegel BA, Strasberg SM. Chemotherapy induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg. 2007;11:1112–9.PubMedCrossRef
15.
Benoist S, Brouquet A, Penna C, Julie C, El Hajjam M, Chagnon S, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? JCO. 2006;24:3939–45.CrossRef
16.
Manfredi S, Lepage C, Hatem C, et al. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244:254–9.PubMedCrossRef
17.
De Jung MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009;2009:440–8.
18.
Nathan H, De Jong MC, Pulitano C, et al. Conditional survival after surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 949 patients. J Am Coll Surg. 2010;210:755–66.PubMedCrossRef
19.
Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;240:309–18.CrossRef
20.
• André T, Boni C, Mounedji-Boudiaf L, et al. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51. Phase III trial that showed FOLFOX adjuvant therapy improves survival in stage III disease. Data may be extrapolated to liver-limited liver resection in stage IV disease.PubMedCrossRef
21.
Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan Fluorouracil Plus Leucovorin Is Not Superior to Fluorouracil Plus Leucovorin Alone As Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803. J Clin Oncol. 2007;25:3456–61.PubMedCrossRef
22.
Ychou M, Raoul J-L, Douillard J-Y, et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol. 2009;20:674–80.PubMedCrossRef
23.
Van Cutsem E, Labianca R, Bodoky G, et al. Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3. J Clin Oncol. 2009;27:3117–25.PubMedCrossRef
24.
Allegra CJ, Yothers G, O'Connell MJ, et al. Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08. J Clin Oncol. 2011;29:11–6.PubMedCrossRef
25.
De Gramont A, Van Cutsem E, Tabernero J, et al. AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer. ASCO Meeting Abstracts. 2011;29:362.
26.
Alberts SR, Sargent DJ, Smyrk CJ, et al. Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol. 2010; 28:(suppl; abstr CRA3507).
27.
Ychou M, Hohenberger W, Thezenas S, et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol. 2009;20(12):1964–70.PubMedCrossRef
28.
Kemeny NE, Jarnagin WR, Capanu M, et al. Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. JCO. 2011;29:884–9.CrossRef
29.
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42.PubMedCrossRef
30.
Van Cutsem E M.D., Ph.D., Köhne C-H M.D., Hitre E M.D., Ph.D., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–17.PubMedCrossRef
31.
Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013–9.PubMedCrossRef
32.
Tveit KM, Guren T, Glimelius B, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin(Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol. 2012;30(15):1755–62.PubMedCrossRef
33.
Maughan TS, Adams RA, Smith CG, et al. MRC COIN Trial Investigators. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomized phase 3 MRC COIN trial. Lancet. 2011;377(9783):2103–14.PubMedCrossRef
34.
Ranpura V MD, Hapani S MD, Wu S MD, PhD. Treatment-related mortality with bevacizumab in cancer patients, a meta-analysis. JAMA. 2011;305(5):487–94.PubMedCrossRef
35.
Pessaux P, Marzano E, Casnedi S, et al. Histological and immediate postoperative outcome after preoperative cetuximab: case matched control study. World J Surg. 2010;34:2765–72.PubMedCrossRef
36.
37.
Berlin J, Van Cutsem E, Peeters M, et al. Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): a pooled analysis of five clinical trials. JCO. 2007; 4134.
38.
Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomized phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006;94(6):798–805.PubMedCrossRef
39.
Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25(13):1670–6.PubMedCrossRef
40.
Vamvakas L, Athanasiadis A, Karampeazis A, Kakolyris S, et al. Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG). Crit Rev Oncol Hematol. 2010;76(1):10.CrossRef
Metadata
Title
Use of Chemotherapy in the Resection of Liver Metastases of Colorectal Cancer
Authors
Anya Litvak
Leonard Saltz
Publication date
01-06-2013
Publisher
Current Science Inc.
Published in
Current Colorectal Cancer Reports / Issue 2/2013
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-013-0160-y

Other articles of this Issue 2/2013

Current Colorectal Cancer Reports 2/2013 Go to the issue

Colorectal Cancer Hepatic Metastases (KK Tanabe, Section Editor)

Management of the Hepatic Lymph Nodes During Resection of Liver Metastases from Colorectal Cancer: A Systematic Review

Localized Rectal Cancer (R Glynne-Jones, Section Editor)

Target Volume Definition in Rectal Cancer: What Is the Best Imaging Modality?

Localized Rectal Cancer (R Glynne-Jones, Section Editor)

How Could the TNM System Be Best Adapted for Staging Rectal Cancer in the Future?

Localized Rectal Cancer (R Glynne-Jones, Section Editor)

Quality of Life and Functions After Chemoradiation for Rectal Cancer: A Review of Recent Publications

Colorectal Cancer Hepatic Metastases (KK Tanabe, Section Editor)

Non-Size-Based Response Criteria to Preoperative Chemotherapy in Patients With Colorectal Liver Metastases: The Morphologic Response Criteria

Localized Rectal Cancer (R Glynne-Jones, Section Editor)

The Role of Enhanced Recovery After Surgery for Rectal Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits